There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Glypican 3

Glypican 3

Glypican 3 Molecule Information

Target Synonym:OCI-5,SGBS1,DGSX,SGBS,SDYS,SGB,MXR7,OCI5,GPC3,Glypican-3,Glypican 3,Glypican Proteoglycan 3,GTR2-2,Secreted Glypican-3,Intestinal protein OCI-5,Heparan Sulphate Proteoglycan
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Phase 2 Clinical

Glypican 3 Protein Product ListCompare or Buy

Glypican 3 Part of Bioactivity data

GP3-HF2H1-Cell-based assay
Evaluation of CAR expression

293 cells were transfected with anti-GPC3-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HF2H1, 3 µg/ml) and C. FITC-labeled Protein Control. A. Non-transfected 293 cells and C. FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-GPC3-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HF2H1) (QC tested).


Anti-human GPC3 MAb (chimeric mouse-human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Glypican 3, His Tag (Cat. No. GP3-H52H4) with an affinity constant of 1.33 nM as determined in a SPR assay (Biacore T200) (Routinely tested).


Anti-Human GPC3 MAb (chimeric mouse-human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Glypican 3 (S359F), His Tag, low endotoxin (Cat. No. GP3-H5223) with an affinity constant of 1.96 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Glypican 3 Customer Reviews

Glypican 3 Molecule Synonym Name


Glypican 3 Molecule Background

Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function.

Glypican 3 References

Glypican 3 Related Molecule

Glypican 3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Yongren Medical Innovation/Guangdong Zhaotai InVivo Biomedicine) Phase 1 Clinical Hunan Zhaotai Medical Group Liver Neoplasms; Lung Neoplasms Details
GPC-3298306 GPC-3298306 Phase 2 Clinical National Cancer Center Of Japan Ovarian Neoplasms; Carcinoma, Hepatocellular Details
Anti-GPC3 CAR T-cell therapy (Nanjing University) Phase 1 Clinical Nanjing University Carcinoma, Hepatocellular Details
GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) Phase 1 Clinical Second Affiliated Hospital Of Guangzhou Medical University Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
GLYCAR T cell therapy (Baylor College of Medicine) GLYCAR Phase 1 Clinical Baylor College Of Medicine Carcinoma, Hepatocellular Details
MDX-1414 MDX-1414 Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
Anti-GPC3 chimeric antigen receptor T cell therapy (Shanghai Genechem) Phase 2 Clinical Shanghai Genechem Co Ltd Liver Neoplasms; Carcinoma, Hepatocellular Details
ERY-974 ERY-974 Phase 1 Clinical Chugai Pharmaceutical Co Ltd Solid tumours Details
Codrituzumab GC-33; RG-7686; RO-5137382 Phase 2 Clinical Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd Carcinoma, Hepatocellular Details
GPC3-CAR-T cell therapy CSG-GPC-3; KJgpc3-001; CAR-GPC3 T-cell; anti-GPC-3 CAR T; GPC3-CAR/CSG-GPC3 Phase 1 Clinical Carsgen Biomedicine (Shanghai) Co Ltd Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
B010-A B010-A Clinical Shanghai Pharmaceuticals Holding Co Ltd Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.